2型糖尿病二线口服降糖药比较效果:基于常规数据的靶试验模拟
该研究利用英格兰2015-21年链接数据模拟靶试验,比较二甲双胍基础上加用磺脲类、DPP-4抑制剂或SGLT-2抑制剂的75 739例2型糖尿病成人。工具变量分析显示SGLT-2抑制剂在降低HbA1c、BMI和收缩压方面优于磺脲类和DPP-4抑制剂,并降低心衰住院(vs DPP-4抑制剂)和eGFR下降风险(vs 磺脲类),但MACE无差异证据。
要点
- SGLT-2抑制剂降HbA1c优于磺脲类(-2.5 mmol/mol)和DPP-4抑制剂(-3.2 mmol/mol)。
- SGLT-2抑制剂降低心衰住院风险优于DPP-4抑制剂(HR 0.32)。
- SGLT-2抑制剂降低eGFR≥40%下降风险优于磺脲类(HR 0.42)。
核心结论
- 在二甲双胍基础上加用SGLT-2抑制剂较磺脲类或DPP-4抑制剂更有效降低HbA1c、BMI和收缩压。
- SGLT-2抑制剂降低心衰住院风险(vs DPP-4抑制剂)和肾脏病进展风险(vs 磺脲类),其他临床终点无差异证据。
研究设计与样本
- 模拟比较效果靶试验的队列研究,使用英格兰2015-21年链接的初级保健、医院和死亡数据。
- 纳入75 739例启动二线口服降糖药(磺脲类、DPP-4抑制剂或SGLT-2抑制剂)联合二甲双胍的2型糖尿病成人。
- 采用工具变量分析减少未观测基线混杂。
主要发现
- SGLT-2抑制剂vs磺脲类HbA1c变化均差-2.5 mmol/mol(95%CI -3.7至-1.3),vs DPP-4抑制剂-3.2 mmol/mol(-4.6至-1.8)。
- SGLT-2抑制剂较磺脲类和DPP-4抑制剂更有效降低BMI和收缩压。
- 心衰住院HR:SGLT-2抑制剂vs DPP-4抑制剂0.32(0.12至0.90),vs磺脲类0.46(0.20至1.05)。
- eGFR≥40%下降HR:SGLT-2抑制剂vs磺脲类0.42(0.22至0.82),vs DPP-4抑制剂0.64(0.29至1.43)。
- MACE的HR:SGLT-2抑制剂vs磺脲类0.99(0.61至1.62),vs DPP-4抑制剂0.91(0.51至1.63)。
临床怎么用
- 对于二甲双胍控制不佳的2型糖尿病患者,二线优先考虑SGLT-2抑制剂可能改善血糖、体重、血压及心衰和肾脏结局。
- 选择二线药物时需结合患者心衰或肾脏病风险个体化决策,同时考虑MACE无差异证据。
局限性
- 为观察性数据模拟靶试验,尽管用工具变量分析,仍可能存在未测量混杂。
- 部分次要终点(如MACE、eGFR vs DPP-4抑制剂)置信区间宽,不确定性高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effectiveness of three commonly prescribed oral antidiabetic drugs added to metformin for people with type 2 diabetes mellitus requiring second line treatment in routine clinical practice. DESIGN: Cohort study emulating a comparative effectiveness trial (target trial). SETTING: Linked primary care, hospital, and death data in England, 2015-21. PARTICIPANTS: 75 739 adults with type 2 diabetes mellitus who initiated second line oral antidiabetic treatment with a sulfonylurea, DPP-4 inhibitor, or SGLT-2 inhibitor added to metformin. MAIN OUTCOME MEASURES: Primary outcome was absolute change in glycated haemoglobin A1c (HbA1c) between baseline and one year follow-up. Secondary outcomes were change in body mass index (BMI), systolic blood pressure, and estimated glomerular filtration rate (eGFR) at one year and two years, change in HbA1c at two years, and time to ≥40% decline in eGFR, major adverse kidney event, hospital admission for heart failure, major adverse cardiovascular event (MACE), and all cause mortality. Instrumental variable analysis was used to reduce the risk of confounding due to unobserved baseline measures. RESULTS: 75 739 people initiated second line oral antidiabetic treatment with sulfonylureas (n=25 693, 33.9%), DPP-4 inhibitors (n=34 464 ,45.5%), or SGLT-2 inhibitors (n=15 582, 20.6%). SGLT-2 inhibitors were more effective than DPP-4 inhibitors or sulfonylureas in reducing mean HbA1c values between baseline and one year. After the instrumental variable analysis, the mean differences in HbA1c change between baseline and one year were -2.5 mmol/mol (95% confidence interval (CI) -3.7 to -1.3) for SGLT-2 inhibitors versus sulfonylureas and -3.2 mmol/mol (-4.6 to -1.8) for SGLT-2 inhibitors versus DPP-4 inhibitors. SGLT-2 inhibitors were more effective than sulfonylureas or DPP-4 inhibitors in reducing BMI and systolic blood pressure. For some secondary endpoints, evidence for SGLT-2 inhibitors being more effective was lacking-the hazard ratio for MACE, for example, was 0.99 (95% CI 0.61 to 1.62) versus sulfonylureas and 0.91 (0.51 to 1.63) versus DPP-4 inhibitors. SGLT-2 inhibitors had reduced hazards of hospital admission for heart failure compared with DPP-4 inhibitors (0.32, 0.12 to 0.90) and sulfonylureas (0.46, 0.20 to 1.05). The hazard ratio for a ≥40% decline in eGFR indicated a protective effect versus sulfonylureas (0.42, 0.22 to 0.82), with high uncertainty in the estimated hazard ratio versus DPP-4 inhibitors (0.64, 0.29 to 1.43). CONCLUSIONS: This emulation study of a target trial found that SGLT-2 inhibitors were more effective than sulfonylureas or DPP-4 inhibitors in lowering mean HbA1c, BMI, and systolic blood pressure and in reducing the hazards of hospital admission for heart failure (v DPP-4 inhibitors) and kidney disease progression (v sulfonylureas), with no evidence of differences in other clinical endpoints.
引用
- Bidulka P, Lugo-Palacios DG, Carroll O, et al. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data. BMJ. 2024. PMID: 38719492. doi:10.1136/bmj-2023-077097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。